ResMed Inc. (NYSE:RMD) will report fiscal Q4 2026 results Aug. 6 after the close and host an investor webcast, even as Morgan Stanley downgraded the stock and trimmed its target, citing margin pressures, a muted outlook, Philips competition in U.S. PAP devices and GLP-1 demand risk.
Previous Week Recap
- ResMed Q4 2026 Earnings Release: ResMed (RMD) to report fiscal Q4 2026 results Aug 6 after NYSE close; company will host an earnings webcast at 1:30 p.m. PT / 4:30 p.m. ET for investors.
- MS Downgrades ResMed On Margin, Outlook: Morgan Stanley downgraded ResMed (RMD) and cut its target, citing concerns about margin growth, a subdued earnings outlook, Philips competing in U.S. PAP devices, and GLP-1–linked demand risk
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original sources.